\
&
Contact us
\
&
Contact us
Published on | 5 years ago
Programmes ICT NMBP SPACE SME Instrument Health Energy Transport Security EIC PilotSmartEEs2, a European acceleration program, is organizing an open Call for Application Experiments with the objective of providing support to Innovative Companies to digitalise their businesses and access new markets by integrating Flexible and Wearable Electronics technologies (FWE) into advanced products / series of products and services.
Interested companies can apply to one of the following two topics:
The SmartEEs2 project would like to directly contribute to reducing spread of COVID–19 and other viruses with flexible & wearable electronics as solutions in the field of prevention, diagnostics, therapy, etc.
Therefore, SmartEEs2 will preferentially support 2 application experiment proposals related to this thematic particularly under the 1st cut-off date 05 June 2020.
For whom? SMEs and Mid-caps, Tech (innovative companies) or non-tech (traditional industries)
When? 5 cut-off dates - first on 5 June 2020
Financial support for an Application Experiment is up to 100 k€
All details on the SmartEEs website
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
